/PRNewswire/ Target RWE, a leading real-world evidence (RWE) solutions company for the healthcare industry, shared results from a recent TARGET-NASH study.
/PRNewswire/ Real-world evidence leader Target RWE announced today COVID-19 data that has been recently published in the peer-reviewed medical journal.
Target RWE Research Presented at DDW 2021 Shows High Rates of Biologic Combination Therapy and Previous Biologic Exposure in IBD Population
Poster of Distinction Award Granted to TARGET-IBD Research
News provided by
Share this article
Share this article
DURHAM, N.C., May 23, 2021 /PRNewswire/ Research presented today at Digestive Disease Week (DDW) 2021 evaluated the prevalence and predictors of immunomodulator use as concomitant therapy with two commonly prescribed biologics, vedolizumab (Entyvio) or ustekinumab (Stelara), in patients with inflammatory bowel disease (IBD). Data from Target RWE s TARGET-IBD large longitudinal cohort
Immunomodulators are Commonly Used as Concomitant Therapy with Vedolizumab or Ustekinumab: TARGET-IBD Real World Cohort was selected for the Poster of Distinction Award.
Patient Determinants for Histologic Diagnosis of Nonalcoholic Fatty Liver Disease in the Real World: A TARGET-NASH Study, aimed to determine patient characteristics that are predictive of having a diagnosis by biopsy versus a diagnosis using clinical criteria.
Analyzing 3,474 participants with NAFLD from August 2016 to March 2019, the study found 67% had not had a liver biopsy.
Analyzing 3,474 adult participants with nonalcoholic fatty liver disease (NAFLD) managed in usual clinical practice from August 2016 to March 2019, the study found 67% of the cohort had not had a liver biopsy. Predictive factors of having a diagnosis by biopsy included White race, female sex, diabetes, and elevated alanine aminotransferase (ALT). Overall, median age was 59 years, 59% were female, 75% White, and 66% obese. The most common comorbid conditions included cardiovascular disease (19%), osteoarthritis (10%), and mental health diagnoses or depression (49%). Of note, patients who had progressed to ci